An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

NCT02473289 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

193

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Sirukumab 50 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC